Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial

Parker Christopher; Finkelstein Steven E.; Michalski Jeff M.; OSullivan Joe M.; Bruland Oyvind; Vogelzang Nicholas J.; Coleman Robert E.; Nilsson Sten; Sartor Oliver; Li Rui; Seger Monica A.; Bottomley David

首页> 外文期刊>European urology >Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial

【24h】

Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial

机译：从3期ALSYMPCA试验中，对有或没有基线阿片类药物使用的有症状去势抵抗性前列腺癌患者使用223-二氯化镭的疗效和安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: The phase 3 ALSYMPCA trial enrolled metastatic castration-resistant prostate cancer patients with or without baseline opioid use.

机译：背景：ALSYMPCA 3期试验招募了有或没有基线阿片类药物使用的转移去势抵抗前列腺癌患者。

著录项

来源
《European urology》 |2016年第5期|共9页
作者
Parker Christopher; Finkelstein Steven E.; Michalski Jeff M.; OSullivan Joe M.; Bruland Oyvind; Vogelzang Nicholas J.; Coleman Robert E.; Nilsson Sten; Sartor Oliver; Li Rui; Seger Monica A.; Bottomley David;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词
ALSYMPCA; Analgesics; Bone metastases; Bone pain; Castration-resistant prostate cancer; External beam radiation therapy; Opioids; Radium-223 dichloride; Skeletal metastases; Symptomatic;

机译：ALSYMPCA;镇痛药;骨转移;骨痛;耐结膜性前列腺癌;外照射疗法;阿片类药物;Radium-223 dichloride;骨骼转移;有症状;

相似文献

外文文献
专利

1. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial [J] . Parker Christopher, Finkelstein Steven E., Michalski Jeff M., European urology . 2016,第5期

机译：从3期ALSYMPCA试验中，对有或没有基线阿片类药物使用的有症状去势抵抗性前列腺癌患者使用223-二氯化镭的疗效和安全性
2. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial [J] . Parker Christopher C., Coleman Robert E., Sartor Oliver, European urology . 2018,第3期

机译：患有抗阉割前列腺癌患者的镭-223二氯化钠的三年安全性来自第3阶段随机癌症癌症试验中的3阶段随机癌症癌症
3. Re: Effect of Radium-223 Dichloride on Symptomatic Skeletal Events in Patients with Castration-Resistant Prostate Cancer and Bone Metastases: Results from a Phase 3, Double-Blind, Randomised Trial [J] . Taneja Samir S. The Journal of Urology . 2015,第3期

机译：回复：二氯化铀223对去势抵抗性前列腺癌和骨转移患者的症状性骨骼事件的影响：三期，双盲，随机试验的结果
4. Castration-Resistant Prostate Cancer: Novel Targets, Agents, and Trials [C] . Evan Y. Yu Genitourinary Cancers Symposium . 2012

机译：抗阉割前列腺癌：新型靶点，药剂和试验
5. Communication preferences, expectations of benefit, and symptom burdens among advanced cancer patients and partners during patient participation in phase I trials [D] . Hlubocky, Fay J. 2010

机译：患者参加I期试验期间，晚期癌症患者及其伴侣之间的沟通偏好，受益期望以及症状负担
6. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases [O] . Hirotsugu Uemura, Hiroji Uemura, Satsohi Nagamori, -1

机译：对日本有症状的去势抵抗性前列腺癌和骨转移患者进行二氯化镭223二期研究的三年随访
7. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial [O] . Parker Christopher, Finkelstein Steven E, Michalski Jeff M, 2016

机译：从3期ALSYMPCA试验中，对有或没有基线阿片类药物使用的有症状去势抵抗性前列腺癌患者使用223-二氯化镭的疗效和安全性

Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial

摘要

著录项

相似文献

相关主题

期刊订阅